Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Immunity. 2021 Aug 10;54(8):1636-1651. doi: 10.1016/j.immuni.2021.07.017. Epub 2021 Aug 3.
The development of effective vaccines to combat infectious diseases is a complex multi-year and multi-stakeholder process. To accelerate the development of vaccines for coronavirus disease 2019 (COVID-19), a novel pathogen emerging in late 2019 and spreading globally by early 2020, the United States government (USG) mounted an operation bridging public and private sector expertise and infrastructure. The success of the endeavor can be seen in the rapid advanced development of multiple vaccine candidates, with several demonstrating efficacy and now being administered around the globe. Here, we review the milestones enabling the USG-led effort, the methods utilized, and ensuing outcomes. We discuss the current status of COVID-19 vaccine development and provide a perspective for how partnership and preparedness can be better utilized in response to future public-health pandemic emergencies.
开发有效的疫苗来对抗传染病是一个复杂的、需要多年时间并涉及多方利益相关者的过程。为了加速针对 2019 年新型冠状病毒病（COVID-19）的疫苗开发，这是一种 2019 年末新出现的病原体，到 2020 年初已在全球范围内传播，美国政府（USG）发起了一项行动，融合了公共和私营部门的专业知识和基础设施。从多种疫苗候选物的快速先进开发中可以看出这一努力的成功，其中一些已显示出疗效，目前正在全球范围内使用。在这里，我们回顾了使美国政府主导的这项工作成为可能的里程碑、所使用的方法以及随之而来的结果。我们讨论了 COVID-19 疫苗开发的现状，并就如何更好地利用合作和准备工作来应对未来的公共卫生大流行紧急情况提供了一个视角。
